Additional Information About the Merger and Where to Find It This presentation relates to the proposed transaction (the "Alcon merger") involving STAAR Surgical Company ("STAAR", "us" or "our"), Alcon Research, LLC, a De

Alcon Merger Maximizes Value for

Stockholders of STAAR Surgical September 2025 Exhibit 99.1

Additional Information About the

Merger and Where to Find It This presentation relates to the proposed transaction (the "Alcon merger") involving STAAR Surgical Company ("STAAR", "us" or "our"), Alcon Research, LLC, a Delaware limited liability company ("Alcon"), and

Rascasse Merger Sub, Inc., a Delaware corporation and a wholly owned direct subsidiary of Alcon ("Merger Sub"). In connection with the proposed transaction, STAAR has filed relevant materials with the U.S. Securities and Exchange

Commission (the "SEC"), including STAAR's definitive proxy statement on Schedule 14A (the "Proxy Statement"), on September 16, 2025. The Proxy Statement was first sent to STAAR stockholders on September 16, 2025. This

presentation is not a substitute for the Proxy Statement or any other document that STAAR may file with the SEC or send to its stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF STAAR ARE

URGED TO READ ALL RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO, IN CONNECTION WITH THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN

IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents (when available) free of charge at the SEC's website, www.sec.gov, or by visiting STAAR's investor relations website,

https://investors.staar.com. No Offer or Solicitation This presentation is for informational purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to

purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or

transfer of securities in any jurisdiction in contravention of applicable law. Participants in the Solicitation Under SEC rules, STAAR and certain of its directors, executive officers and other members of management and employees may be deemed to be

participants in the solicitation of proxies from the holders of STAAR's common stock in connection with the proposed transaction. Information about the directors and executive officers of STAAR and their ownership of STAAR's common stock is set

forth in the Proxy Statement, the definitive proxy statement for STAAR's 2025 Annual Meeting of Stockholders (the "Annual Proxy Statement"), which was filed with the SEC on April 24, 2025 (and which is available at

https://www.sec.gov/ix?doc=/Archives/edgar/data/0000718937/000095017025058174/staa-20250424.htm), including the sections captioned "Compensation of Directors," "Information Regarding Executive Officers" and "Security

Ownership of Principal Shareholders and Management," or its Annual Report on Form 10-K for the year ended December 27, 2024, which was filed with the SEC on February 21, 2025 (and which is available at

https://www.sec.gov/ix?doc=/Archives/edgar/data/0000718937/000095017025024813/staa-20241227.htm), and in other documents filed by STAAR with the SEC. To the extent holdings of such participants in STAAR's securities have changed since the amounts

described in the Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC by STAAR's directors and executive officers. These documents

can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be

contained in other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. Forward-Looking Statements The information covered by this presentation contains forward-looking statements within the

meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as "anticipate," "believe," "expect," "plan," "estimate,"

"project," "continue," "will," "should," "may," and similar terms. All statements in this presentation that are not statements of historical fact are forward-looking statements. These

forward-looking statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from what is

expressed or implied by the forward-looking statements, including, but not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Alcon merger agreement or could cause the

consummation of the proposed transaction to be delayed or to fail to occur; (2) the failure to obtain approval of the proposed transaction from STAAR's stockholders; (3) the failure to obtain certain required regulatory approvals or the failure to

satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all; (4) risks related to disruption of management's attention from STAAR's ongoing business operations due to the

proposed transaction; (5) the effect of the announcement of the proposed transaction on the ability of STAAR to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its

operating results and business generally; (6) the ability of STAAR to meet expectations regarding the timing and completion of the transaction; (7) the outcome of any legal proceedings that may be instituted against STAAR related to the proposed

transaction; (8) the possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated; (9) the demand for ICLs in China and macroeconomic trends in China; (10) risks associated with new, existing and

improved products in U.S. or international markets or governmental approval of new or improved products; and (11) other important factors set forth in the Proxy Statement under the caption "Risk Factors" and STAAR's Annual Report on Form

10-K for the year ended December 27, 2024 under the caption "Risk Factors," as any such factors may be updated from time to time in STAAR's other filings with the SEC. This presentation contains estimates, projections and other

information concerning the ophthalmic industry, our business, and the markets for certain medical conditions, procedures, and products. Information that is based on estimates, forecasts, projections, market research or similar methodologies is

inherently subject to uncertainties and actual events or circumstances may differ materially from the estimates and forecasts reflected in this information. Forward-looking statements speak only as of the date they are made and, except as may be

required under applicable law, STAAR undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

STAAR's Board of Directors

Unanimously Believes the Alcon Merger Provides Greater Value than STAAR Could Achieve on a Standalone Basis in the Foreseeable Future and is the Best Path Forward for STAAR Stockholders $28.00 per share all-cash consideration provides stockholders

compelling, certain, immediate cash value at a significant premium STAAR's Board conducted a thoughtful evaluation of strategic alternatives over an extensive time period and negotiated favorable terms with Alcon that maximize value for STAAR

stockholders For more than a year before entering into the Alcon merger agreement, STAAR's Board considered strategic alternatives available to STAAR Considered various risk-adjusted growth scenarios and implications for STAAR's

standalone value creation opportunity Analyzed industry landscape and universe of potential buyers Negotiated high premium value and favorable agreement terms Mitigated risks of conducting full pre-signing sales process by negotiating an extended

45-day "window shop" and low break-up fees STAAR faces sustained challenges as a standalone company, and management projections do not signal a return to historical growth rates or profitability I II III IV Claims by Broadwood Partners

are flawed and misleading and reflect a misunderstanding of STAAR's standalone challenges, value, and potential buyer interest in STAAR EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS Other than

Alcon, STAAR has not received any acquisition proposal in at least the last 10 years. Despite media reports of a takeover of STAAR over a year ago and an extended "window shop" period under the Alcon merger agreement, STAAR has still not

received any competing proposals.

STAAR designs, develops, manufactures,

and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. STAAR's Implantable Collamer Lenses (ICLs) are made from Collamer, a proprietary collagen copolymer material created and

used exclusively by STAAR to make our lenses soft, flexible, and biocompatible with the eye. ICLs are implanted during a minimally invasive surgical procedure. STAAR generates nearly all of its Net Sales from its EVO and EVO+ ICLs, which are

designed to treat myopia (nearsightedness), with and without astigmatism. In certain countries, STAAR also sells ICLs to treat hyperopia (farsightedness) and myopia with presbyopia. STAAR ICLs are phakic lenses, meaning that they are implanted into

the eye without removing the eye's natural crystalline lens. STAAR Surgical Overview FY24 Net Sales $313.9 M FY24 Net Loss $(20.2) M FY20-FY25 Net Sales $ in millions China Rest of World FY24 Net Sales by Geography(1) 51% China | 13% Japan |

7% Korea | 6% U.S. | 22% Rest of World May not sum to 100% due to rounding. Reflects management projections in the definitive proxy. Reflects a burn down of distributor inventory. (2) EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL

EVALUATION | BROADWOOD CLAIMS

Represents a significant premium

across multiple measures and a price meaningfully higher than the market's expectations prior to the Alcon merger announcement, particularly given STAAR's lower go-forward growth profile. On February 11, 2025, after STAAR announced its

4Q 2024 results, STAAR's stock price declined to $15.09 and traded in the range of $15.09 to $20.27 through the date of the Alcon merger announcement on August 5, 2025. Executive Summary Based on 90-day VWAP for period ending August 4, 2025,

which was the day before announcement. Based on August 4, 2025, closing price, which was the day before announcement. Based on available brokers with current price targets as of August 1, 2025. Median premium paid of 26% across comparable

transactions. Comparable transactions based on U.S. cash-only MedTech deals announced since 2015 with deal value above $500mm. $28.00 per share all-cash consideration provides STAAR stockholders compelling, certain, and immediate cash value at a

significant premium. premium to median sellside analyst price target of $19(3) median premium paid in comparable transactions(4) premium to 90-Day VWAP of $18(1) premium to unaffected share price(2) 59% 51% 47% ~2.0x I EXECUTIVE SUMMARY | PREMIUM

VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

STAAR faces sustained challenges as a

standalone company and management projections do not signal a return to historical growth rates or profitability. Although management has made progress mitigating some near-term challenges, STAAR faces ongoing business headwinds that will continue

to impact results. The Board believes the certain $28.00 per share all-cash consideration provided by the Alcon merger agreement exceeds what STAAR could achieve on a standalone basis in the foreseeable future. Executive Summary 04 06 STAAR has

overweight exposure to China, where growth has slowed and macroeconomic conditions, new market entrants, and the resulting potential for pricing pressure are creating greater risks and headwinds. 02 The TAM for myopia is large, but the number of

refractive surgery procedures remains small, and STAAR competes with large, well resourced, global companies that offer numerous treatment options. 05 01 STAAR's operating and financial results over the last several years have been

inconsistent and impacted by challenges facing the business, which has led to stock price declines. Alcon's resources will enable STAAR to accelerate adoption of EVO ICL by surgeons and patients. II 03 STAAR's consignment inventory has

mitigated the potential impact of China tariffs in the short term, though medium- and long-term global tariff risk still exists, especially in an unpredictable geopolitical environment. STAAR has a limited product offering, derives nearly all of its

Net Sales from EVO and EVO+ ICLs, and has largely been ineffective in diversifying through new product introductions and R&D efforts. While EVO ICLs can be used across varying levels of myopia severity, in the 10+ years since launch, STAAR has

not been able to penetrate the market beyond high myopia patients. STAAR's Sustained Challenges EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

STAAR's Board conducted a

thoughtful evaluation of strategic alternatives over an extensive time period and negotiated favorable terms with Alcon that maximize value for STAAR stockholders. Entry into the Alcon merger agreement followed more than a year of consideration by

STAAR's Board of strategic alternatives available to STAAR. Amidst STAAR's declining performance, STAAR's Board negotiated favorable agreement terms focused on maximizing value and certainty. Executive Summary Other than Alcon,

STAAR has not received any acquisition proposal in at least the last 10 years. Despite media reports of a takeover of STAAR over a year ago and an extended "window shop" period under the Alcon merger agreement, STAAR has still not

received any competing proposals. Favorable Terms For STAAR Stockholders Included In Alcon Merger Agreement III Allows Competing Offers At any time prior to the stockholder vote, STAAR's Board is able to consider competing offers and terminate

the Alcon merger agreement to accept a superior proposal "Window Shop" Provision Allows for post-signing market check with nominal break-up fees of $14.5M (1%) for certain proposals received during 45-day "window shop" period and $43.4M

(3%) for proposals received thereafter No "Naked No Vote" Fee No obligation of STAAR for expense reimbursement or other fee payable to Alcon if STAAR stockholders do not approve the merger Limited Conditionality Provides for limited

conditionality, Alcon regulatory commitments, and $72M (5%) break-up fee payable by Alcon to STAAR in certain circumstances due to failure to receive regulatory approvals EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION |

Claims by Broadwood Partners are

flawed and misleading and reflect a misunderstanding of STAAR's standalone challenges, value, and potential buyer interest in STAAR. Broadwood believes that STAAR's near-term prospects will drive a higher stock price and that now is the

wrong time to transact. STAAR's Board and management team understand STAAR's business risks and challenges better than Broadwood. STAAR believes the $28.00 per share consideration provides STAAR stockholders greater value than STAAR

could achieve on a standalone basis in the foreseeable future. Executive Summary Broadwood is asking stockholders to forfeit the all-cash, premium value provided by the Alcon merger and bear STAAR's significant risks as a standalone company.

Claims By Broadwood Partners IV "Deficient Process" STAAR's Board conducted an extensive review process that considered standalone prospects, the industry landscape, and potential buyers. Merger agreement terms were aggressively

negotiated to protect premium value in hand while allowing for a post-signing market check "Wrong Time to Transact" STAAR's 2Q25 results reflected incremental progress in addressing challenges, but did not signal a return to

historical growth or profitability. While some issues in China have been addressed, 2Q25 and 3Q25 trends reinforce STAAR's Net Sales challenges. There is no "market moving" clinical trial "Inadequate Price" The Alcon

merger agreement maximizes value with a compelling price at a significant premium to the price that had been established by an efficient market. Broadwood's claimed value is not supported by STAAR's actual financial performance "Windfall for

Executives" Neither STAAR's Board nor management team changed any component of executive compensation, including change-in-control provisions in connection with the transaction. Alcon's election to cash-out employee equity awards

applies equally to all employees O O O O EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

STAAR expects that its valuation would

face considerable downward pressure in the event of a vote against the deal STAAR's future direction controlled by a single minority stockholder at the expense of the majority Risk of creeping control by Broadwood a likely drag on valuation

Ongoing risks related to standalone prospects Threatened dismissal of existing Board and management, with new team hand-picked by Broadwood given Broadwood's significant input on STAAR over 30+ years, it is unclear how STAAR's

other stockholders would benefit from even greater control by Broadwood Lengthy and significant disruption to patients, surgeons, employees, distributors, partners and stockholders Vote Against Vote For Certain and immediate cash value Significant

premium by any measure Attractive valuation multiple De-risks standalone plan and addresses headwinds Accelerates ICL adoption by more surgeons for the benefit of more patients worldwide Unanimously recommended and approved by STAAR's

independent and experienced Board O P $28.00 per share all-cash offer $18.49 per share prior to announcement If the Alcon merger agreement is terminated, it could be a deterrent to any future buyers. Not only is there a risk of damage to potential

future sale processes, but there is no guarantee that Alcon would participate in any future process. EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS Alcon is paying STAAR stockholders a 59% premium to

the 90-day VWAP. Broadwood's proposal to vote down the merger could allow Broadwood to take control without paying any premium to other stockholders.

The Alcon Merger Provides

Compelling, Certain, and Immediate Cash Value at a Significant Premium, Particularly Given STAAR's Lower Go-Forward Growth Profile EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

All-cash Alcon merger consideration

of $28.00 per share is a compelling premium across multiple measures Deal Price vs 90-Day VWAP 59% Premium to 90-Day VWAP(1) Deal Price vs Sell-side Price Target 47% Premium to Median Price Target(2) Premium vs. Comparable Transactions Based on

90-day VWAP for period ending August 4, 2025, which was the day before announcement. Based on available brokers with current price targets as of August 1, 2025. Median premium paid of 26% across comparable transactions. Comparable transactions based

on U.S. cash-only MedTech deals announced since 2015 with deal value above $500mm. ~2.0x Median Premium Paid in Comparable Transactions(3) Significant premium to STAAR stock price and significantly higher than comparable all-cash MedTech

transactions. EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

Independent analysts recognize the